Search

Medtronic MiniMed Inc. has been issued a patent for a glucose estimation technique that does not require continuous glucose monitoring. The patent describes a method that involves receiving input data from a user, such as discrete blood glucose measurements and contextual data, and using an estimation model to generate real-time estimated blood glucose values. These estimated values can then be used to control an insulin delivery device. The technique aims to provide a more affordable alternative to continuous glucose monitoring systems, making it accessible to a larger group of users. [Extracted from the article]

A patent application titled "Network Topology For Insulin Pump Systems" has been published online. The application describes systems, devices, and methods for insulin pump systems that allow a durable controller device to securely communicate with a mobile computing device and various peripheral devices using a common wireless communication standard. The durable controller can manage the delivery of insulin locally, make dosing determinations, and control the operation of the insulin pump. The use of a single chipset and interface for communication can reduce costs, minimize power consumption, and increase battery life. The patent application also mentions the use of a mobile application and a cloud service to store and communicate patient information. [Extracted from the article]

A patent has been issued for systems, devices, and methods for integrating an analyte data reader and medication delivery device. The patent, assigned to Abbott Diabetes Care Inc., aims to address the need for an integrated device that can monitor analyte levels and administer medication, such as insulin, for individuals with diabetes. The integrated device has a small form factor, similar to an insulin pen, and can wirelessly communicate with a sensor control device worn on the body. The patent also includes methods for preventing medication injection during adverse conditions and obtaining recent analyte level data. [Extracted from the article]

Becton Dickinson and Company has been issued a patent for a medical device that delivers drug therapy to individuals with diabetes. The device utilizes capacitive coupling communication and energy harvesting, and includes a microcontroller, pump mechanism, transceiver, and power supply system. It communicates with a host device through a personal area network and is powered by energy harvested from the user's body. This patent application highlights the use of proinsulin, a peptide hormone, in the device, which could potentially enhance healthcare and medical treatment options. [Extracted from the article]

Tandem Diabetes Care Inc. has been granted a patent for a sleep mode in their automated insulin delivery system. This sleep mode adjusts the glucose target and range to accommodate the specific needs during sleep. The patent outlines different methods for transitioning to sleep mode, such as considering the time since the last insulin dose, using algorithms to predict low glucose levels, and estimating the amount of insulin in the user's body. These methods aim to improve glucose control without increasing the risk of hypoglycemia. The patent also describes an ambulatory infusion pump system that delivers insulin based on glucose levels from a continuous glucose monitor. The system includes a processor that calculates insulin doses to maintain glucose levels within a target range. If necessary, the system can adjust the target range immediately or gradually based on the time since the last insulin delivery. The patent was filed by Alexandra Elena Constantin and published in April 2024. [Extracted from the article]

DexCom Inc. has been issued a patent for methods of providing alerts or alarms to users of mobile communications devices. The patent specifically focuses on managing data communication between software apps on a computing device for continuous glucose monitoring in diabetes care. This technology allows users to seamlessly monitor their glucose levels and receive alerts or alarms when levels reach a certain threshold, eliminating the need for a separate display device. The patent also includes features such as encryption for secure data transmission and the ability to escalate alerts if they are not acknowledged within a certain time period. The document provides detailed descriptions of the method and system, as well as different implementation options. [Extracted from the article]

A patent has been issued to Tandem Diabetes Care Inc. for methods of incorporating continuous glucose monitoring (CGM) data into diabetes therapy. The patent describes an ambulatory infusion pump system that automatically calculates insulin doses based on glucose levels received from a CGM device and delivers the doses to the user. The system includes a bolus programming feature that can be automatically populated with the most recent glucose level from the CGM device, but only if certain predefined conditions are met to ensure the accuracy and reliability of the data. This technology aims to improve the safety and convenience of insulin delivery for individuals with diabetes. [Extracted from the article]

A patent application titled "Infusion Pump Systems And Methods" has been published online by the US Patent and Trademark Office. The patent application describes an infusion pump system that can accurately determine the total insulin load (TIL) in a user's body, taking into account both bolus and basal insulin dosages, as well as previous food intake. The system includes a user interface that displays the user's blood glucose level and TIL, allowing for informed decision-making. Additionally, the system can suggest a bolus dosage based on the user's TIL and other factors. The patent application was filed by inventor Mark C Estes. [Extracted from the article]

Researchers have submitted a patent application for a wearable non-invasive blood glucose monitoring system. The system aims to provide a reliable and easy-to-use alternative to current glucose monitoring devices. It involves continuously capturing a photoplethysmography signal of a patient in real-time, inputting blood pressure measurement, demographic information, and the photoplethysmography signal into a mobile application, transmitting this information to a cloud server, and generating a glucose prediction of the patient based on the input information. The system has the potential to improve diabetes management and enhance the quality of life for diabetic patients. [Extracted from the article]

Tandem Diabetes Care, Inc. has issued a recall for Version 2.7 of the Apple iOS t:connect mobile app used with the t:slim X2 insulin pump with Control-IQ technology. The recall is due to a software problem that can cause the app to crash and drain the pump's battery, potentially leading to a shutdown of the pump and under-delivery of insulin. This can result in hyperglycemia or diabetic ketoacidosis. There have been 224 reported injuries but no deaths associated with this issue. Users are advised to update the app, monitor the pump's battery level, and carry backup supplies for insulin delivery. [Extracted from the article]

A patent has been issued to DexCom Inc. for an analyte sensor with impedance determination. The patent describes systems, devices, and methods for using impedance or conductance measurements in a glucose sensor. The sensor can assess membrane integrity and determine the presence of damage or abnormality in the sensor membrane. This technology has potential applications in managing blood glucose levels for diabetes patients. [Extracted from the article]

This document provides information about a clinical trial, NCT06384911, that aims to investigate the effectiveness of a financial incentives program called InvesT1D in improving diabetes self-management in adolescents with type 1 diabetes. The trial will randomly assign participants to either usual care or the financial incentives program and compare changes in glucose levels and person-reported outcomes between the two groups. The trial will also assess various outcome measures, including time in range, hemoglobin A1c levels, and quality of life. The goal is to understand if financial incentives can help adolescents with their daily self-management of diabetes. The trial is being conducted by Seattle Children's Hospital in collaboration with Harvard Pilgrim Health Care and is expected to be completed by February 2028. [Extracted from the article]

A patent has been issued to Abbott Diabetes Care Inc. for systems and methods for using insulin information for meal indication. The invention aims to provide a glucose report based on large amounts of glucose data, showing patterns and analyses of the glucose history of a patient to aid in treatment considerations. The system includes a processor, non-volatile memory, and display to analyze and visually present glucose data and analytics. The method involves storing glucose data, collecting insulin timing information, identifying meal-related glucose data, performing pattern analysis, and providing treatment recommendations based on the number of rise or fall patterns detected. [Extracted from the article]

A patent application has been submitted for the invention of a system that automatically detects when a meal has not been properly bolused for individuals with diabetes. The system utilizes continuous glucose monitoring (CGM) data to determine if a meal has been consumed within a specific time period and if a bolus has been delivered. If no bolus has been delivered and the CGM data exceeds a certain threshold, the system provides a reminder to the user to deliver the bolus. The invention aims to improve diabetes therapy by ensuring proper medication delivery. [Extracted from the article]

A patent has been issued to DexCom Inc. for a time-averaged basal rate optimizer. The patent describes a method for optimizing a basal rate profile for continuous insulin therapy. The method involves periodically updating the basal rate profile based on a retrospective analysis of continuous glucose sensor data and adjusting the profile in response to real-time glucose sensor data indicating hyperglycemia or hypoglycemia. This technology aims to improve the accuracy and effectiveness of insulin dosing for individuals with diabetes. [Extracted from the article]

A patent has been issued to Bigfoot Biomedical Inc. for insulin injection assistance systems, methods, and devices. The patent aims to address the challenges faced by individuals with diabetes in determining appropriate doses of insulin. The invention includes a recommendation system that analyzes glucose data and timing information to provide adjustment recommendations for insulin delivery. The system can be used with manual insulin delivery devices and incorporates user-friendly interfaces to simplify therapy management. The patent also mentions the potential for the system to be adapted for the delivery of other medications and the treatment of other diseases. [Extracted from the article]

This document provides information about a research study on the effects of driving on individuals with type 1 diabetes. The study aims to assess the frequency of hypoglycemia during driving periods and other related outcomes. The study will involve participants who use an insulin pump and continuous glucose monitoring. Data will be collected and analyzed anonymously to ensure privacy and confidentiality. The study is not yet recruiting participants and is expected to be completed by May 2026. [Extracted from the article]

The patent application titled "Systems And Methods For Automatically Assisting Patients" discusses the use of data collection platforms in healthcare to collect and analyze healthcare-related data. These platforms can be used with medical devices to deliver therapies and monitor patient conditions. The application also proposes a triage system to prioritize patient interventions based on their condition and interaction with the system. The goal is to improve the management and assistance provided to remotely managed patient populations. The method involves identifying issues affecting patient satisfaction and providing educational material and troubleshooting recommendations to improve outcomes. [Extracted from the article]

A patent application has been submitted for a system and method that aims to improve the management and assistance provided to remotely managed patient populations. The system combines data collection with therapy, such as an implanted neuromodulator or an insulin pump, to determine a triage tier for intervention by a clinician or device representative. The method involves delivering therapy, assessing the patient's condition, receiving patient interaction, and using both the condition and interaction to assign a priority ranking for intervention. The patent application provides detailed information on the different components and processes involved in the system. [Extracted from the article]

This document provides information about a clinical trial at the University of Missouri, Kansas City, that aims to evaluate a behavioral treatment program for adult patients with type 2 diabetes. The study will assess if the program, which includes diabetes coaching, financial rewards, and continuous glucose monitoring, improves adherence to a diabetes treatment plan and blood sugar management. Participants will wear a continuous glucose monitor and receive diabetes coaching and financial rewards, while the control group will only wear the monitor and continue with their usual treatment. The trial is expected to be completed by December 31, 2024. [Extracted from the article]

A patent application by Becton Dickinson and Company has been made available online for a cannula insertion detection device. The device aims to ensure that a cannula, catheter, or probe reaches the proper insertion depth and can detect if it is oriented at an angle. The invention includes an insertion monitor with electrical contacts or mechanical posts that provide indication of the cannula insertion status. The device also includes an alert mechanism to notify the user if the cannula is incorrectly inserted. [Extracted from the article]

A patent has been issued to Abbott Diabetes Care Inc. for systems, devices, and methods for managing glucose levels. The patent describes the use of user interface input mechanisms with haptic feedback capabilities to improve functionality and privacy for patients. The glucose management devices include a user interface controlled by a processor, with a touch screen display that visually displays a graph of glucose levels and provides haptic feedback in response to user input. The patent also mentions the use of insulin infusion pumps and continuous glucose monitoring devices in conjunction with the user interface. [Extracted from the article]

A patent application has been published online for a system that continuously monitors glucose levels in diabetic individuals. The system includes a sensor, transmitter, and data processing module, and displays the data graphically on a mobile device. The display can show patterns in the data and relationships between insulin, glucose, and events. This technology has the potential to improve glucose monitoring for diabetics. The article discusses the application of software for data visualization in the field of health and medicine, specifically for analyzing peptide hormone data. [Extracted from the article]

A recent study conducted by the University of Messina in Italy explores the development of an artificial pancreas for individuals with type 1 diabetes. The researchers highlight the challenges involved in designing and developing such a device, including the need for an accurate mathematical model of the patient's physiology. The study provides a comprehensive overview of recent advances in modeling biological processes and developing nonlinear control strategies for the artificial pancreas. The researchers also emphasize the importance of real-time parameter estimation, effective uncertainty management, and in-depth clinical studies to assess the efficacy and safety of the device. The study concludes by discussing the potential for control techniques that address individual patient conditions and enable personalized diabetes management. [Extracted from the article]

A patent has been issued to Medtronic MiniMed Inc. for a combined device that includes an analyte sensor and an infusion set hub. The device is designed to manage the lack of insulin in individuals with diabetes by delivering insulin subcutaneously. The analyte sensor monitors glucose levels in the interstitial fluid and can transmit data to a monitor or recording device. The device is modular, allowing for individual replacement of either the analyte sensor or the infusion set hub. The patent provides detailed descriptions and claims for the device. [Extracted from the article]

A patent application titled "Fluid Infusion Systems" has been published online by the US Patent and Trademark Office. The application describes a portable fluid infusion device, such as an insulin pump, that is more convenient and easier to use for users. The device includes features such as a planar battery, a user interface without a display, and the integration of an infusion set with a physiological characteristic sensor. The application also discusses wearable fluid infusion devices and fluid infusion systems that can be adhesively coupled to a user's anatomy. The invention aims to improve the convenience, usability, and cost-effectiveness of fluid infusion devices. [Extracted from the article]

A clinical trial, NCT06347783, is being conducted to examine the impact of insulin pumps on sleep in children with type 1 diabetes and their caregivers. The trial aims to determine whether insulin pumps have a positive, negative, or neutral effect on sleep quality, as well as explore the connection between insulin pumps, sleep, and overnight blood sugar control. Participants will be asked to complete questionnaires, surveys, wear a FitBit during sleep, and maintain daily sleep diaries. The trial is observational and will last for four months. This document provides information about a research study that is not yet recruiting participants. The study aims to investigate the relationship between sleep and type 1 diabetes in children and adolescents. The study will include participants aged 6-18 who have been diagnosed with type 1 diabetes for at least 6 months and are currently receiving treatment through multiple daily injections of insulin. Participants will be required to have smartphone access and download the FitBit application. The study will collect data through surveys and a daily sleep diary. The estimated completion date for the study is December 15, 2024. [Extracted from the article]

A recent study conducted at the University of Michigan evaluated the feasibility and performance of continuous glucose monitoring (CGM) to guide computerized insulin infusion therapy in the cardiovascular intensive care unit. The study found that CGM, when combined with periodic point-of-care blood glucose tests, was accurate and convenient for both nurses and patients. The results suggest that adopting CGM in postoperative care could improve workflow, enhance health outcomes, and be cost-effective. Further research is needed to confirm these findings. [Extracted from the article]

A patent application has been submitted for an apparatus and methods to maintain and clean medical devices. The invention aims to address concerns related to blood-borne pathogen disease transmission, particularly in scenarios where components of a continuous glucose monitor (CGM) may be used by multiple users. The invention includes an enclosure for the CGM, with covers and adhesives to secure the device and prevent contamination. The patent application also describes a method for reprocessing reusable electronic medical devices and a protective case with a lock to deter device removal. [Extracted from the article]

A patent application titled "Methods For Reduction of Battery Usage In Ambulatory Infusion Pumps" has been published online. The application discusses the need for conserving battery power in ambulatory infusion pumps, which are used for delivering fluids in medical treatments. The invention proposes systems and methods for conserving battery life by limiting data transfers between the infusion pump and other devices, such as smartphones and cloud storage services. The patent application provides detailed descriptions and claims for various embodiments of the invention. [Extracted from the article]

A recent report discusses research findings on the accuracy of continuous glucose monitoring (CGM) devices in pediatric diabetic ketoacidosis (DKA) admissions. The study compared point-of-care glucose values to personal Dexcom G6 sensor data during hospitalizations. The results showed that CGM accuracy is similar between DKA and non-DKA admissions, as well as during severe DKA and IV insulin administration. However, further research is needed to determine the feasibility of implementing CGM in hospitals. This study was conducted by researchers at the University of Colorado Anschutz Medical Campus and was supported by the NIH National Institute of Diabetes & Digestive & Kidney Diseases and the Juvenile Diabetes Research Foundation. [Extracted from the article]

A clinical trial, NCT06334484, has been launched to evaluate the effect of an advanced hybrid closed loop system on adjunctive continuous glucose monitoring metrics in individuals with type 1 diabetes mellitus. The trial aims to assess the glycemic improvement expressed through standardized metrics such as time spent within optimal glucose range, time below target glucose range, and time above target glucose range. The advanced hybrid closed loop system combines insulin pump infusion and real-time continuous glucose monitoring data to optimize glycemic control. The trial is currently in the recruitment phase and is expected to be completed by March 2026. [Extracted from the article]

DexCom Inc. has been issued a patent for systems and methods that enhance the visualization and interpretation of health data for continuous glucose monitoring. The system includes a sensor, transmitter, and data processing module that continuously monitor glucose levels and display graphical representations of the data on mobile devices. The system can analyze the data based on various factors and provide user support tools such as trend graphs and colored displays. This technology aims to improve the understanding of health data for individuals using continuous glucose monitoring devices. [Extracted from the article]

This document provides information about a clinical trial, NCT06319300, that aims to evaluate the use of an artificial intelligence-assisted insulin dose adjustment system in hospitalized patients with Type 2 diabetes. The trial will compare the outcomes of patients whose insulin doses are adjusted by the AI system versus those whose doses are adjusted by doctors. The trial is not yet recruiting participants and is expected to be completed by May 2026. The document also includes eligibility criteria for participants and administrative information about the trial. Keywords associated with the trial include hospitals, Type 2 diabetes, machine learning, and clinical research. [Extracted from the article]

A patent application titled "Recyclable Device For Deploying Transcutaneous Sensors And Related Technology" has been published online. The inventor, Ellis Garai, filed the application on September 7, 2022, and it became available on March 7, 2024. The patent application describes a deployment device for transcutaneous sensors used in monitoring blood glucose levels in diabetic patients. The device aims to improve the convenience and sustainability of deploying transcutaneous devices for diabetes management. It includes a housing, plunger, frame, cap, spring, carrier, and stop, and allows for easy connection and removal of the transcutaneous device. [Extracted from the article]

The U.S. Food and Drug Administration has cleared the Dexcom Stelo Glucose Biosensor System, the first over-the-counter continuous glucose monitor (CGM). This integrated CGM is intended for individuals 18 years and older who do not use insulin, such as those with diabetes managing their condition with oral medications or individuals without diabetes who want to understand how diet and exercise affect blood sugar levels. However, the system is not designed to alert users to low blood sugar. The device uses a wearable sensor and a smartphone application to continuously measure and display glucose values. Users should consult their healthcare provider before making medical decisions based on the device's output. The FDA's director of the Center for Devices and Radiological Health, Jeff Shuren, stated that this clearance expands access to CGMs and promotes health equity for U.S. patients. [Extracted from the article]

This document provides information about a clinical trial, NCT06295289, that is currently recruiting participants in China. The trial aims to compare the use of a hybrid closed-loop insulin delivery system with standard insulin therapy in controlling glucose levels among perioperative patients with diabetes. The goal is to evaluate the clinical efficacy and safety of the hybrid closed-loop system and compare blood glucose control and postoperative complications. The trial is expected to be completed by December 2024 and includes eligibility criteria for participants and contact information for the primary investigator. [Extracted from the article]

A patent application has been submitted for a system and method that aims to improve alerts for users with diabetes. The current monitoring devices have limitations, such as uncomfortable finger pricks and the potential for users to ignore or turn off alerts. This system seeks to address these issues by providing personalized alerts based on the user's cognitive awareness, resulting in fewer unnecessary alarms. The application provides detailed information about the method and system, including the factors and data sources used for estimating cognitive awareness. [Extracted from the article]

A patent has been issued to DexCom Inc. for a system and method for mode switching in an artificial pancreas system. The patent describes a device that can transition between different modes of user interaction based on the usability of sensor data. This allows for more dynamic and intelligent monitoring of glucose levels in individuals with diabetes. The system can switch between therapeutic and adjunctive modes, providing different levels of user interaction and visual indications of glucose concentration. The patent also mentions the use of real-time usability data and various triggers for mode switching. [Extracted from the article]

Bigfoot Biomedical Inc. has been granted a patent for a diabetes therapy management system that aims to simplify insulin therapy for individuals with diabetes. The system includes an insulin delivery device with a cap detector and dosing event detector, as well as a transmitter for sending dosing data to a remote device. The remote device has a receiver and display for showing dosing data and recommendations. The system offers different insulin container options and can provide visual and audible indications for dosing events. [Extracted from the article]

Medtronic MiniMed Inc. has submitted a patent application for a removable wearable device and related attachment methods. The device is designed to provide a stable and durable connection to the body for accurate monitoring and treatment of chronic diseases. The device includes a skin adhesive, a durable component, and an interface component that allows for easy removal of the durable component. The patent application provides detailed descriptions and claims for the device and its components. This information may be useful for researchers and individuals interested in healthcare technology and medical devices. [Extracted from the article]

A patent has been issued to Medtronic MiniMed Inc. for infusion system consumables and related calibration methods. The patent describes a method and apparatus for accurately monitoring and controlling the volume of fluid delivered by an infusion device without the need for a costly flow meter. The invention involves obtaining calibration data associated with a consumable, determining a delivery command based on the calibration data, and operating a pumping mechanism to deliver the fluid in accordance with the command. This technology has potential applications in the healthcare industry, particularly for delivering insulin to diabetic patients. [Extracted from the article]

A recent study from the Division of Endocrinology examined the effects of early time-restricted eating (TRE) combined with daily caloric restriction (DCR) compared to DCR alone on continuous glucose levels. The study involved 81 adults with overweight or obesity who were randomized into two groups. The results showed no significant differences in glucose profiles or insulin sensitivity between the two groups after 12 weeks. However, it is important to note that the study sample included participants with normal baseline glucose profiles and insulin sensitivity, which may have limited the ability to detect changes in these outcomes. [Extracted from the article]

A patent has been issued for a microneedle enclosure and applicator device for a microneedle array-based continuous analyte monitoring device. The patent was filed by Biolinq Incorporated and published online on February 20, 2024. The invention aims to improve analyte monitoring for diabetic patients by providing a more accurate and less invasive method of measuring blood glucose levels. The device includes an applicator with a housing, cuff, and shuttle, which allows for easy and precise application of the monitoring device to the skin surface. This innovation addresses the limitations of current continuous glucose monitoring devices, such as tissue trauma and signal latency. [Extracted from the article]

A patent application titled "Analyte Sensor" has been published online by the US Patent and Trademark Office. The patent application, filed by inventors Bradley Liang, Shaun Pendo, Rajiv Shah, and Katherine Wolfe, aims to simplify the insertion process for continuous glucose monitoring (CGM) and artificial pancreas therapy. The invention involves a sensor assembly with a piercing member and a sensor on a flexible substrate, as well as a method of inserting the sensor into the subdermal space. The patent application provides detailed descriptions and claims for the sensor assembly and method. [Extracted from the article]

A recent study conducted by Dexcom Inc. has found that continuous glucose monitoring (CGM) can reduce the incidence of hospitalizations for patients with type 2 diabetes (T2D) and chronic kidney disease (CKD). The study analyzed US administrative claims data and identified 8,959 insulin-using patients with T2D and CKD who initiated CGM. After CGM initiation, rates of hospitalizations for hyperglycemia or hypoglycemia decreased by 18.2% and 17.0% respectively. The study concludes that CGM could help individuals with T2D and CKD control their glucose levels and avoid dangerous glycemic events. [Extracted from the article]

A clinical trial has been launched in Finland to determine the impact of using the FreeStyle Libre 2 glucose monitoring system on HbA1c levels in adults with type 2 diabetes treated with basal insulin. The study will last for three months and participants will use the monitoring system to track their glucose levels. The primary outcome measure will be the change in HbA1c within the group from baseline. The trial is not yet recruiting and is expected to be completed in January 2025. [Extracted from the article]

A patent application has been submitted for a medical device system that includes a body-wearable medical device and a disposable container. The system is designed to help patients manage their health conditions by providing access to additional drugs or foodstuff in case of emergencies. The disposable container has a tamper-evident closure and can be fastened to the body-wearable medical device. The container is intended for one-time use and can be easily disposed of after the contents have been withdrawn. The system aims to increase patient safety and reduce the burden of carrying multiple devices and accessories. [Extracted from the article]

A patent application has been submitted for a system and method for fluid delivery in the treatment of medical conditions such as diabetes. The system includes a medical fluid pump, continuous analyte monitors, and a controller. The controller uses data from the analyte monitors to determine the appropriate delivery of medical fluid. The invention aims to improve the management of diabetes by providing more accurate and controlled insulin delivery. The patent application was filed by inventors from New Hampshire and is currently awaiting approval. [Extracted from the article]

A patent has been issued to Becton Dickinson and Company for a cannula insertion detection device. The device aims to ensure that a cannula, catheter, or probe reaches the proper insertion depth and can detect if it is oriented at an angle. It includes sensors and an alert mechanism to provide feedback on the insertion status. The patent provides detailed descriptions and claims for the device. [Extracted from the article]